causal
Narrow-spectrum cures clash with broad-spectrum profit demand
A recurring obstacle for new treatments like lysin and phage therapy is that pharmaceutical companies want broad-spectrum drugs that can cure all bacterial infections, whereas cures for specific pathogens (MRSA, Lyme, Candida auris) are narrow-spectrum, expensive to produce, and less profitable, so they must be incentivized like orphan diseases.
causalpending
Speaker
Matt McCarthyEvidence Quote
“the big companies want broad spectrum treatments... those are very narrow spectrum and that means that they're not going to make as much money off of them”
Created: 6/14/2026, 2:12:29 AM
Your notes
Loading notes...